EMD Doses First Patient in MDMA Clinical Trial
Next Investors
Oct 09, 2023
Today, our biotech Investment, Emryia (ASX: EMD) has successfully dosed its first patient in a Phase 2b trial using MDMA for the treatment of Post Traumatic Stress Disorder (PTSD).
